Table 2.
Primary and secondary outcomes by monoclonal antibody treatment status for primary cohort.
| Outcome | Sotrovimab-Treated | Untreated | Adjusted Odds Ratio | 95% CI |
|---|---|---|---|---|
| Overall Sample Size | N = 1542 | N = 3663 | ||
| All-Cause 28-Day Hospitalization (Primary Outcome) | 39 (2.5%) | 116 (3.2%) | 0.82 | (0.55, 1.19) |
| All-Cause 28-Day Mortality | 1 (0.1%) | 7 (0.2%) | 0.62 | (0.07, 2.78) |
| Any Emergency Department Visit to Day 28 | 93 (6.0%) | 224 (6.1%) | 1.03 | (0.79, 1.32) |
| Hospitalized Sample Size | N = 39 | N = 116 | ||
| Hospital LOS Days, Mean (SD) | 5.2 (6.8) | 7.3 (7.7) | – | – |
| High-Flow Nasal Cannula /Non-invasive Ventilation, Invasive Mechanical Ventilation or Death | 6 (15.4%) | 33 (28.4%) | – | – |
| ICU Admission | 4 (10.3%) | 20 (17.2%) | – | – |
| ICU LOS Days, Mean (SD) | 1.5 (0.58) | 8.1 (14.04) | – | – |
All regression models adjusted for age, sex, race/ethnicity, obesity, immunocompromised status, number of comorbidities, insurance status, and vaccination status.
Abbreviations: ICU, intensive care unit; LOS, length of stay.